Newswire (Published: Thursday, March 19, 2020, Received: Thursday, March 19, 2020, 5:15:49 PM CDT)

Word Count: 443

2020 MAR 19 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Daily -- Researchers detail new data in Oncology - Prostate Cancer. According to news reporting originating from Toronto, Canada, by NewsRx correspondents, research stated, “DNA sequencing has identified recurrent mutations that drive the aggressiveness of prostate cancers. Surprisingly, the influence of genomic, epigenomic, and transcriptomic dysregulation on the tumor proteome remains poorly understood.”

Funders for this research include Prostate Cancer Canada, Canadian Institutes of Health Research, Ontario Ministry of Health and Long-Term Care, Natural Sciences and Engineering Research Council of Canada, Canada Foundation for Innovation, Movember Foundation, Government of Canada, Ontario Genomics Institute, Canadian Cancer Society, National Cancer Institute Early Detection Research Network, Princess Margaret Cancer Centre.

Our news editors obtained a quote from the research from Ontario Institute for Cancer Research, “We profiled the genomes, epigenomes, transcriptomes, and proteomes of 76 localized, intermediate-risk prostate cancers. We discovered that the genomic subtypes of prostate cancer converge on five proteomic subtypes, with distinct clinical trajectories. ETS fusions, the most common alteration in prostate tumors, affect different genes and pathways in the proteome and transcriptome. Globally, mRNA abundance changes explain only 10% of protein abundance variability.”

According to the news editors, the research concluded: “As a result, prognostic biomarkers combining genomic or epigenomic features with proteomic ones significantly outperform biomarkers comprised of a single data type.”

For more information on this research see: The Proteogenomic Landscape of Curable Prostate Cancer. Cancer Cell, 2019;35(3):414-427.e6. Cancer Cell can be contacted at: Cell Press, 1100 Massachusetts Ave, Cambridge, MA 02138, USA. (Elsevier - www.elsevier.com; Cancer Cell - http://www.journals.elsevier.com/cancer-cell/)

The news editors report that additional information may be obtained by contacting V. Huang, Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada. Additional authors for this research include A. Sinha, J. Livingstone, J. Wang, N.S. Fox, N. Kurganovs, V. Ignatchenko, K. Fritsch, N. Donmez, L.E. Heisler, Y.J. Shiah, C.Q. Yao, J.A. Alfaro, S. Volik, A. Lapuk, M. Fraser, K. Kron, A. Murison, M. Lupien and S.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.ccell.2019.02.005. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Cancer Cell is: Cell Press, 1100 Massachusetts Ave, Cambridge, MA 02138, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Long Term Care Group Inc.
Government of Canada
Canadian Cancer Society

Places

North America
Canada
United States
Americas
Ontario
Massachusetts
Toronto
Cambridge

Subjects

Science and Technology
      Scientific Research
            Medical Research
      Sciences
            Natural Sciences
                  Biology
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Genetics
                  Genomics
            Medical Research
Politics and Government
      Government Agencies (Non-U.S.)